In Clark et al. (2017)[1](#acn3490-bib-0001){ref-type="ref"} figure legends for figure 5 and 6 were incorrectly published on pages 581--582.

Legends for figure 5 and 6 were switched and should have read as:

Figure 5. Impaired FXN processing from FXN^42--210^ to FXN^81--210^ occurs in fibroblasts from FRDA patients with FXN^G130V^. FXN levels were quantified by western blot using whole cell extracts from control (CTRL), FRDA, and G130V patient fibroblasts. CTRL = 5 fibroblast lines (*n *=* *13), G130V = 3 lines (*n *=* *17), and Typical = 7 lines (*n* = 8). (A) FXN^42--210^ (18 kD), and FXN^81--210^ (13 kD) levels from control (CTRL), G130V, and typical FRDA were detected from whole cell extracts by western blot using an anti‐FXN antibody. Detection of GAPDH serves as a loading control. FXN levels are quantified and expressed as a ratio of FXN^42--210^ to FXN^81--210^. (\*) = *P *\<* *0.05. (B). Confocal microscopy images of patient fibroblasts (CTRL, FRDA, and G130V) that were fixed and stained using primary anti‐FXN and primary antimitofusin antibodies. Secondary antibodies included Alexa Fluor 568 (FXN) and Alexa Fluor 488 (mitofusin). DAPI was also used as a nuclear stain.

Figure 6. Increasing FXN^G130V^ and FXNI^154F^ FXN^1--210^ levels does not increase FXN^81--210^ levels. Following transfection of HEK 293 cells with mutant FXN constructs, cells were treated with 10 lmol/L MG132 proteasome inhibitor for 5 h followed by cell lysis. Exogenous FXN^1--210^ (23 kD), FXN^42--210^ (19 kD), and FXN^81--210^ (15 kD) levels, before and after treatment, were detected by western blot using a primary anti‐HA antibody.

We apologize for these errors.
